{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-007190","form_type":"8-K","ticker":"ELTP","cik":"0001053369","company_name":"ELITE PHARMACEUTICALS INC /NV/","filed_at":"2026-02-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.472764+00:00","generated_at":"2026-05-16T02:18:31.435926+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Elite Pharma Q3 FY2026 revenue up 120% to $31.6M; net income $18.6M","bullets":["Revenue $31.6M, +120% YoY; income from operations $9.0M, +721% YoY.","Net income $18.6M for three months ended Dec 31, 2025.","Growth driven by lisdexamfetamine and naltrexone product launches after prior year comparable period.","Conference call Feb 18, 2026 at 11:30 AM EST; questions due by Feb 17 evening."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-007190","json":"https://secwatch.observer/filing/0001493152-26-007190.json","markdown":"https://secwatch.observer/filing/0001493152-26-007190.md","text":"https://secwatch.observer/filing/0001493152-26-007190.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053369/000149315226007190/0001493152-26-007190-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053369/000149315226007190/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T02:18:31.435926+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}